Research indicates that blocking the RAGE pathway can attenuate the progression of aortic valve calcification, suggesting a therapeutic target for CAVD (Deng et al. 2020). The gene discussed is AGER; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.